Extensions for Using Data Elements from FHIR DSTU2 in FHIR R4B - Downloaded Version null See the Directory of published versions
| Official URL: http://hl7.org/fhir/uv/xver/ValueSet/R2-v3-substanceAdminSubstitution-for-R4B | Version: 0.1.0 | |||
| Standards status: Trial-use | Maturity Level: 0 | Computable Name: R2V3SubstanceAdminSubstitutionForR4B | ||
This cross-version ValueSet represents content from http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31 for use in FHIR R4B.
This value set is part of the cross-version definitions generated to enable use of the
value set http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31 as defined in FHIR DSTU2
in FHIR R4B.
The source value set is bound to the following FHIR DSTU2 elements:
Across FHIR versions, the value set has been mapped as:
http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2016-11-11http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution|2018-08-12Note that all concepts are included in this cross-version definition because no concepts have compatible representations
Following are the generation technical comments:
All concepts in the comparison are listed as identical.
The source and target value sets have the same number of active concepts (9).
All concepts in the comparison are listed as identical.
The source and target value sets have the same number of active concepts (9).
FHIR ValueSet http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31, defined in FHIR DSTU2 does not have any mapping to FHIR R4B
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
http://hl7.org/fhir/v3/substanceAdminSubstitution version 📍1.0.2| Code | Display | Definition |
| BC | brand composition | Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven |
| E | equivalent | Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. |
| EC | equivalent composition | Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril |
| F | formulary | Description: This substitution was performed or is permitted based on formulary guidelines. |
| G | generic composition | Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) |
| N | none | No substitution occurred or is permitted. |
| TB | therapeutic brand | Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet |
| TE | therapeutic alternative | Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet |
| TG | therapeutic generic | Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine |
| _ActSubstanceAdminSubstitutionCode | ActSubstanceAdminSubstitutionCode | Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. |
This value set expansion contains 10 concepts.
| System | Version | Code | Display | Definition | JSON | XML |
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | BC | brand composition | Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | E | equivalent | Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | EC | equivalent composition | Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | F | formulary | Description: This substitution was performed or is permitted based on formulary guidelines. | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | G | generic composition | Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | N | none | No substitution occurred or is permitted. | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | TB | therapeutic brand | Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | TE | therapeutic alternative | Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | TG | therapeutic generic | Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine | ||
http://hl7.org/fhir/v3/substanceAdminSubstitution | 1.0.2 | _ActSubstanceAdminSubstitutionCode | ActSubstanceAdminSubstitutionCode | Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |